Rusfertide Poised to Ease Phlebotomy Burden in PV Care

In an interview, Abdulraheem Yacoub, MD, highlighted the potential of rusfertide to reshape treatment for patients with polycythemia vera (PV), particularly those reliant on frequent phlebotomy. Drawing on patient feedback from clinical studies, Yacoub emphasized that enthusiasm for the therapy has been consistently strong, with many participants expressing a desire to remain on rusfertide after trial completion.

He pointed to patients managed with phlebotomy alone as the most immediate candidates for treatment. These individuals—often considered lower risk and typically younger than 60 without a history of thrombosis—currently undergo regular procedures to control hematocrit levels. Rusfertide, administered as a once-weekly self-injection, offers a more convenient alternative that could replace routine visits to infusion or phlebotomy centers.

According to Yacoub, the therapy’s tolerability profile has also contributed to patient interest. Aside from mild injection-site discomfort, rusfertide has not been associated with significant constitutional adverse effects in studies to date. This contrasts with the logistical and physical burden of phlebotomy, which can require time off work and may be followed by fatigue or other side effects.

Beyond this initial population, Yacoub noted that rusfertide may also benefit patients already receiving cytoreductive therapies who continue to require frequent phlebotomy. In these cases, the agent could be added to existing treatment regimens to reduce procedure frequency and improve quality of life.

As data continue to emerge, rusfertide appears positioned to address a longstanding unmet need in PV care by minimizing reliance on phlebotomy and offering patients a more flexible, at-home treatment option.